Trial Profile

A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Pemetrexed vs Placebo Combined With Carboplatin and Pemetrexed as First-line Therapy in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 08 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Catequentinib (Primary) ; Pemetrexed (Primary) ; Penpulimab (Primary)
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Sponsors Akeso Biopharma

02 Apr 2024 Status changed from active, no longer recruiting to discontinued.
11 Oct 2022 The number of treatment arms increased from 2 to 3. Anlotinib has been introduced in the treatment.
11 Oct 2022 Planned End Date changed from 30 Nov 2021 to 30 Jun 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com